April 1st 2023
The collaboration, titled the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), is the first public-private partnership designed to advance lupus discoveries and highlight patient perspective in drug development.
Quantifying the Association Between Anxiety and Depressive Features and High Disease Activity Scores in SLEJanuary 19th 2023
Anxiety and depression can limit engagement with healthcare or treatment leading to later diagnosis, poor treatment adherence, and poor disease control with associated negative sequelae.
Risk of Pregnancy Complications Greater in Women with Systemic Lupus ErythematosusJune 18th 2022
Data from an analysis of the National Inpatient Sample provides insight into the risk of pregnancy complications among women with systemic lupus erythematosus compared to their counterparts without systemic lupus erythematosus in the US over a decade-long period.
Albert Roy: Clinically Significant Phase 2 Data Evaluates Deucravacitinib for SLE TreatmentJune 3rd 2022
Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.
Lupus Nephritis: TULIP-LN Hints at a Blossoming Role for AnifrolumabMay 10th 2022
In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.
From Living BLISSfully to BEATing Lupus: Future Considerations for Biologic Therapy in SLEMay 9th 2022
After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.
TeleLupus in the Context of COVID-19: Is There a Long-Term Role for Remote Consultation in How We Manage Lupus Patients?April 21st 2022
Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.
Easy-BILAG: Fast Scoring, Faster Decisions in LupusMarch 1st 2022
"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."